
The annual BHF conference is taking place in Cape Town from 14 -17 May 2023. Networking, collaboration and learning about emerging healthcare issues, innovation and industry action, and discussions regarding what’s next.
Recent Posts
European Immunotherapy Approval for Ovarian Cancer: KEYTRUDA’s New Role in Treating PD-L1-P...
Immunotherapy ovarian cancer treatment has taken a major step forward in Europe. The European Commission has approved KEYTRUDA (pembrolizumab) in combination with paclitaxel, with or without bevacizumab, for adults with PD-L1 CPS ≥1 platinum-resistant recurrent ovarian, fallopian tube, or primary...
Facilitating Reimbursement for Intravesical Gemcitabine in Bladder Cancer Treatment
Reimbursement Bladder Cancer advances with the assignment of a permanent HCPCS J-code for INLEXZOâ„¢ (gemcitabine intravesical system), effective April 1, 2026. This standardized billing code simplifies reimbursement bladder cancer treatment for adult patients with BCG-unresponsive non-muscle invas...
100% Tariffs Impacting Pharmaceutical Manufacturing and National Security
President Donald J. Trump has imposed tariffs on patented pharmaceutical products and their ingredients, using tariffs pharmaceutical manufacturing policy to protect national security and strengthen U.S. supply chains. The move applies a baseline 100% tariff on patented pharmaceuticals, with lowe...